Targenta
Targenta Ltd has developed an online medical service for patients with a known or suspected medical diagnosis which helps to navigate in the labyrinth of private medical services. We would like to offer our expertise, the power of our proprietary databases and our robust software solutions to find the truly relevant local examinations, healthcare providers, and diagnostic methods for a given complex medical condition.
We take patients’ general physical state, chronic co-morbidities, health insurance options, tax refund status, possible implants, and special sensitivities into consideration, which personalization saves the patients countless dead-ends on the traditionally crooked patient pathway and ultimately, worrying, time and money.
Our mission and vision are to help patients and their families to live longer and higher-quality lives by providing personalized, interactive medical maps covering their relevant opportunities and to provide a platform for the emerging Central and Eastern European medical service market to show its excellent qualities and extensive opportunities to all Customers in Europe.
Our main services are Personal Medical Condition Summaries and Personalized Medical Reports.
Personal Medical Condition Summaries convert the User’s medical and associated data to a 1-pager format synopsis with which one can easily find any medical specialist, since it includes every information needed for a briefing before an examination but doesn’t contain any unnecessary data that would distract or otherwise hamper the process.
Personalized Medical Reports contain the following elements: a map which shows the relevant local services, and a modular list of services with the following crucial info: service price, detailed contact info (link and phone numbers), is it diagnostics or treatment, how invasive it is, is hospitalization needed or not, etc. For detailed info on this topic visit our Services page here
Personalized Medical Reports may come with an expert validation or can be supplemented with written or oral report explanation, medical report translation, and other customary services. For the list of supplementary services visit our Services page here
To patients and their families, who would like to save time and money
Patients who would like to avoid dead-ends, unnecessary information, and charlatans
To patients who are tired of the gratitude money system and would like to use clean services instead of hoping for privileged treatment
Patients whose problem needs quicker solutions than what government institutes are able to provide
Patients and relatives who experience communication gaps with medical personnel
Those who are willing to experience technologically advanced, quality solutions
Molecular Biologist graduated at Eötvös Loránd University, Faculty of Science | PhD studies specializing in molecular diagnostics at Semmelweis University | Business studies at Semmelweis Innovations & InCorpora
Highlighted Publications:
Targeted drug combination therapy design based on driver genes. Zsákai L et al., Oncotarget, 2019
Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes. Simon-Szabó L et al., Bioorg Med Chem Lett. 2016
Complex regulation of autophagy in cancer – integrated approaches to discover the networks that hold a double-edged sword. Kubisch J et al., Sem Cancer Biol. 2013
Developing FGFR4 inhibitors as potential anti-cancer agents via in silico design, supported by in vitro and cell-based testing. Ho HK et al., Curr Med Chem. 2013
Mycobacterium tuberculosis ellenes hatoanyagok fejlesztése es szerkezet-hatás összefuggéseinek vizsgálata. Baska F et al., Acta Pharm Hung. 2013
SignaLink 2 – a signaling pathway resource with multi-layered regulatory networks. Fazekas D et al., BMC Syst Biol. 2013
Potenciális antitumor hatású FGFR inhibitorok fejlesztése, Zsákai L et al., Acta Pharm Hung. 2013
Patents (applied as an Inventor):
WO2017153789: Benzo[b]thiophene derivatives and their use for the inhibition of Fibroblast Growth Factor Receptor kinases (FGFRs) for the use of neo- and hyperplasia
WO2015019121: Styrylquinazoline derivatives as pharmaceutically active agents
P1500431: Pyrido pyrimidine derivatives as pharmaceutically active agents
P1500620: Novel use of kinase antagonist compounds to alter fibrotic cell proliferation
Neurobiologist graduated at the University of Szeged, Department of Medical Chemistry | PhD degree in the area of neurological disorders, University of Szeged, Department of Medical Chemistry
Highlighted Publications:
Interactions of pathological hallmark proteins: tubulin polymerization promoting protein/p25, beta-amyloid, and alpha- synuclein. Oláh J, et al., J Biol Chem. 2011
A foldamer-dendrimer conjugate neutralizes synaptotoxic β-amyloid oligomers. Fülöp L et al., PLoS One. 2012
Protein array based interactome analysis of amyloid-β indicates an inhibition of protein translation. Virok DP et al., J Proteome Res. 2011
Two pyridine derivatives as potential Cu(II) and Zn(II) chelators in therapy for Alzheimer's disease. Lakatos A et al., Dalton Trans. 2010
Controlled in situ preparation of A beta(1-42) oligomers from the isopeptide "iso-A beta(1-42)", physicochemical and biological characterization. Bozso Z et al., Peptides. 2010
Pharmacist graduated at Semmelweis University | PhD degree in Pathobiochemistry
Highlighted Publications:
A novel drug discovery concept for tuberculosis: Inhibition of bacterial and host cell signalling. Székely R et al., Immunology Letters, 2008
Regulation of influenza A virus mRNA splicing by CLK1. Artarini A et al., Antiviral research 2019
Investigation of the mode of action of sunitinib kinase inhibitor profile analogues in insulin release. Orfi Z et al. European Journal of Cancer, 2014
Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. E Herczenik, Z Varga, D Erős, V Makó, M Oroszlán, S Rugonfalvi-Kiss: Journal of Receptors and Signal Transduction 29 (2), 75-83, 2009
Binding specificity of the L-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1. Erős D et al., Amino acids, 2009
Signal transduction therapy with rationally designed kinase inhibitors. Keri G et al., Current Signal Transduction Therapy, 2006
Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosis. Hegymegi-Barakonyi B et al., Curr Med Chem. 2008;15(26):2760-70
Targeted drug combination therapy design based on driver genes, Zsákai L et al., Oncotarget, 2019
Reliability of logP predictions based on calculated molecular descriptors: A critical review. Erős D et al, Curr. Med. Chem. 2002
Evaluation of lipophilicity and antitumour activity of parallel carboxamide libraries. Hollósy F et al., Journal of Chromatography B, 2002
Relationship between lipophilicity and antitumor activity of molecule library of Mannich ketones determined by high- performance liquid chromatography, clogP calculation and cytotoxicity test. Hollósy F et al., Journal of Chromatography B, 2002
Evaluation of hydrophobicity and antitumor activity of a molecule library of Mannich ketones of cycloalkanones. Hollósy F et al., Journal of Liquid Chromatography and Related Technologies, 2002
Biological activity and structure of antitumor compounds from Plantago media. Kunvari M et al., Acta Pharmaceutica Hungarica, 1999
Comparison of Predictive Ability of Water Solubility QSPR Models Generated by MLR, PLS and ANN Methods. Erős D et al., Mini-Reviews in Medicinal Chemistry 2004
Determination of the basicity of Mannich ketones by capillary electrophoresis. Dobos Zs et al., Journal of Chromatography B, 2004
Comparison of measured and calculated lipophilicity of substituted aurones and related compounds. Hallgas B et al., Journal of Chromatography B, 2004
Rational Drug Design and Signal Transduction Therapy. Erős D et al., Pharmacem, 2004
Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Szekelyhidi Z et al., Bioorg Med Chem Lett. 2005 Jul 1;15(13):3241-6.
Characterization of lipophilicity and antiproliferative activity of E-2-arylmethylene-1-tetralones and their heteroanalogues. Hallgas B et al., J Chromatogr B Analyt Technol Biomed Life Sci. 2005
Prediction oriented QSAR modelling of EGFR inhibition. Szantai-Kis C et al., Curr. Med. Chem., 2006
MIF tautomerase inhibitor potency of alpha,beta-unsaturated cyclic ketones. Garai J et al., Int Immunopharmacol.
Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor. Kiss R et al., Eur J Med Chem. 2007
Drug discovery in the kinase inhibitory field using the Nested Chemical Library technology. Kéri G et al., Assay Drug Dev Technol. 2005
Structure –Activity Relationships of PDE5 Inhibitors. Erős D et al., Current Medicinal Chemistry, Volume 15, Number 16, 2008. Pp. 1570-1585.
Binding specificity of the L-arginine transport systems in mouse macrophages and human cells overexpressing the cationic amino acid transporter hCAT-1. Erős D et al., Amino Acids. 2009
Protein kinase inhibitor-induced endothelial cell cytotoxicity and its prediction based on calculated molecular descriptors. Herczenik E et al., Journal of Receptors and Signal Transduction, 2009
Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. Hegymegi-Barakonyi B et al., Curr Opin Mol Ther. 2009
Patents (registered as an Inventor):
EP3056202: Benzopyrolidone derivatives possessing antiviral and anticancer properties
Scientific Translator graduated at the University of Szeged | Neurobiologist MSc at University of Szeged | PhD studies in the field of Neuroscience at University of Szeged | Business Informatics at Budapest Business School
On technical issues, please contact us via admin@targenta.org
On medical and business issues, please contact Lilian ZSÁKAI: lilian.zsakai@targenta.org, +36304284142
On legal and accountancy issues please contact us via admin@targenta.org or via post
our Szeged Headquarters: H-6726, 11/D Alsó Kikotő sor, Szeged, Hungary
our Budapest office: H-1074, 9. I.4. Barát str, Budapest, Hungary
Full name: Targenta Korlátolt Felelősségű Társaság
Year of establishment: 2019
Registered seat: H-6726, 11/D Alsó Kikötő sor, Szeged, Hungary
VAT number: 27285736-2-06
Main activity: 7219 Other research and experimental development on natural sciences and engineering